Experience Shapes Use of Dual Immunotherapy in Advanced Melanoma
Source: Targeted Oncology, February 2024
During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed what patient factors and other considerations affect the choice of immunotherapy for patients with advanced BRAF-negative melanoma. This is the first of 2 articles based on this event.
DISCUSSION QUESTION
- Have you had the opportunity to use nivolumab plus relatlimab (Opdualag) in patients with advanced melanoma?
ANKIT MANGLA, MD: It was pretty smooth immunotherapy for a dual checkpoint inhibition. There weren’t many adverse events [AEs]; maybe grade 1 skin rash. I’ve not used it very commonly, but I’ve probably had 3 or 4 patients on it and not [seen] more than that. It’s not the rough course we sometimes see with the ipilimumab [Yervoy] at 3 mg and nivolumab [Opdivo] at 1 mg. Fatigue is common…but apart from that, so far, we have not had a grade 3 or grade 4 event. But our experience is only with 3 to 4 patients; we have not used it that much.